61 related articles for article (PubMed ID: 25344677)
21. Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.
Sklarz LM; Gladbach YS; Ernst M; Hamed M; Roolf C; Sender S; Beck J; Schütz E; Fischer S; Struckmann S; Junghanss C; Fuellen G; Murua Escobar H
Cancer Cell Int; 2020; 20():390. PubMed ID: 32817744
[TBL] [Abstract][Full Text] [Related]
22. Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis.
Nam HY; Chandrashekar DS; Kundu A; Shelar S; Kho EY; Sonpavde G; Naik G; Ghatalia P; Livi CB; Varambally S; Sudarshan S
Mol Cancer Res; 2019 Jan; 17(1):84-96. PubMed ID: 30131446
[TBL] [Abstract][Full Text] [Related]
23. Expression of K
Vázquez-Sánchez AY; Hinojosa LM; Parraguirre-Martínez S; González A; Morales F; Montalvo G; Vera E; Hernández-Gallegos E; Camacho J
Oncol Lett; 2018 May; 15(5):6302-6308. PubMed ID: 29849783
[TBL] [Abstract][Full Text] [Related]
24. Pan-organ transcriptome variation across 21 cancer types.
Hu W; Yang Y; Li X; Zheng S
Oncotarget; 2017 Jan; 8(4):6809-6818. PubMed ID: 28036280
[TBL] [Abstract][Full Text] [Related]
25. KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma.
Guo Z; Liu J; Zhang L; Su B; Xing Y; He Q; Ci W; Li X; Zhou L
Tumour Biol; 2015 Feb; 36(2):1251-9. PubMed ID: 25344677
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma.
Zhang HM; Yang FQ; Chen SJ; Che J; Zheng JH
Tumour Biol; 2015 Apr; 36(4):2947-55. PubMed ID: 25480417
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma.
Xu GH; Lou N; Shi HC; Xu YC; Ruan HL; Xiao W; Liu L; Li X; Xiao HB; Qiu B; Bao L; Yuan CF; Zhou YL; Hu WJ; Chen K; Yang HM; Zhang XP
BMC Cancer; 2018 Jan; 18(1):88. PubMed ID: 29357836
[TBL] [Abstract][Full Text] [Related]
28. MEIS1 inhibits clear cell renal cell carcinoma cells proliferation and in vitro invasion or migration.
Zhu J; Cui L; Xu A; Yin X; Li F; Gao J
BMC Cancer; 2017 Mar; 17(1):176. PubMed ID: 28270206
[TBL] [Abstract][Full Text] [Related]
29. hZIP1 that is down-regulated in clear cell renal cell carcinoma is negatively associated with the malignant potential of the tumor.
Dong X; Kong C; Zhang Z; Liu X; Zhan B; Chen Z; Shi D
Urol Oncol; 2014 Aug; 32(6):885-92. PubMed ID: 24878177
[TBL] [Abstract][Full Text] [Related]
30. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
Ma X; Fan Y; Gao Y; Zhang Y; Huang Q; Ai Q; Ni D; Chen W; Zhang P; Song E; Wang B; Shi T; Zheng T; Zhang X
Urol Oncol; 2014 Jan; 32(1):46.e9-17. PubMed ID: 24094887
[TBL] [Abstract][Full Text] [Related]
31. Calcium intake and ion transporter genetic polymorphisms interact in human colorectal neoplasia risk in a 2-phase study.
Zhu X; Liang J; Shrubsole MJ; Ness RM; Cai Q; Long J; Chen Z; Li G; Wiese D; Zhang B; Smalley WE; Edwards TL; Giovannucci E; Zheng W; Dai Q
J Nutr; 2014 Nov; 144(11):1734-41. PubMed ID: 25165391
[TBL] [Abstract][Full Text] [Related]
32. Nephrocalcinosis as adult presentation of Bartter syndrome type II.
Huang L; Luiken GP; van Riemsdijk IC; Petrij F; Zandbergen AA; Dees A
Neth J Med; 2014 Feb; 72(2):91-3. PubMed ID: 24659592
[TBL] [Abstract][Full Text] [Related]
33. Identification of compound heterozygous KCNJ1 mutations (encoding ROMK) in a kindred with Bartter's syndrome and a functional analysis of their pathogenicity.
Srivastava S; Li D; Edwards N; Hynes AM; Wood K; Al-Hamed M; Wroe AC; Reaich D; Moochhala SH; Welling PA; Sayer JA
Physiol Rep; 2013 Nov; 1(6):e00160. PubMed ID: 24400161
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.
Valletti A; Gigante M; Palumbo O; Carella M; Divella C; Sbisà E; Tullo A; Picardi E; D'Erchia AM; Battaglia M; Gesualdo L; Pesole G; Ranieri E
PLoS One; 2013; 8(10):e78452. PubMed ID: 24194935
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
